SCHEMBL5216688

SCHEMBL5216688

Cn1cc(C(O)c2cn(C(c3ccccc3)(c3ccccc3)c3ccccc3)cn2)cc1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
FNTA P49354 2/20 0.35
FNTB P49356 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
CYP2C9 P11712 2/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
SIRT2 Q8IXJ6 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216640 0.81 CYP2C9 (0.41) HTTNPC1RAB9AFNTAFNTB
SCHEMBL5224020 0.78 NPC1 (0.39) HTTNPC1RAB9ASMN1; SMN2CYP2C9
SCHEMBL2202154 0.74 CYP11B1 (0.40) SMN1; SMN2LMNASIRT2
SCHEMBL313050 0.73 ACSS2 (0.42) SIRT2ACSS2
SCHEMBL5220913 0.73 HTT (0.47) HTTNPC1RAB9ASMN1; SMN2CYP2C9
SCHEMBL21636129 0.71 SIRT2 (0.35) SIRT2KMT2AMEN1ACSS2
SCHEMBL30994944 0.70 CYP19A1 (0.39) SMN1; SMN2CYP1A2MAPTTSHRCYP2C19
SCHEMBL845130 0.70 CYP11B1 (0.43) HTTRAB9ASMN1; SMN2CYP2C9USP2
SCHEMBL1737415 0.70 KDM4E (0.40) LMNAMAPTSIRT2
SCHEMBL8114076 0.69 FGFR1 (0.36) SMN1; SMN2LMNACYP1A2CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458386-B1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO MCNEIL PHARM INC (US) 2007-04-18 EP disclosed
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed
US-6897319-B2 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-05-24 US disclosed
US-6867198-B2 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY (US) 2005-03-15 US disclosed
EP-1458386-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER Ortho-McNeil Pharmaceutical, Inc. (US) 2004-09-22 EP disclosed
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-25 US disclosed
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY 2003-12-11 US disclosed
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-25 US disclosed
WO-2003057219-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO-MCNEIL PHARMACEUTICAL INC. (US) 2003-07-17 WO disclosed
WO-2003057147-A2 USEFUL AROYL PYRROLE HETEROARYL METHANONES AND METHANOLS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-07-17 WO disclosed
EP-1242420-A2 AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2002-09-25 EP disclosed
WO-2001044247-A2 AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HTT 542/4885NPC1 1743/4885RAB9A 1671/4885
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HTT 542/4885NPC1 1743/4885RAB9A 1671/4885
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HTT 542/4885NPC1 1743/4885RAB9A 1671/4885
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases MKI67, CDKN1A, CDK1 HTT 2946/4885NPC1 865/4885RAB9A 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.